Novartis' Janneke van der Kamp joins Grünenthal as new CCO

German family-owned drugmaker Grünenthal today announced that Janneke van der Kamp will join the company as the new chief commercial officer (CCO), effective March 1, 2023.

Ms van der Kamp joins Grünenthal from Swiss pharma giant Novartis (NOVN: VX), where she most recently served as head of Pharma Region Europe. A Dutch native, she brings broad experience in the pharmaceutical industry from several roles including general manager, global neurosciences franchise head and global head of product and portfolio strategy for the entire Novartis Pharma portfolio. She worked closely with R&D and the licensing and acquisitions teams to strengthen the company’s pipeline.

As CCO of Grünenthal, which specializes in pain management, Ms van der Kamp will be responsible for the entire global commercial organization and serve as a member of the corporate executive board. Her focus will be to continue to grow the company’s key brands, prepare for the launch of Grünenthal’s pipeline assets and maximise the portfolio of established medicines.